

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
The Bay City Capital Fund III, L.P.		12/14/2005	LIMITED PARTNERSHIP: DELAWARE
RECEIVING PARTY DATA			
Name:	Syntonix Pharmaceuticals, Inc.		
Street Address:	9 Fourth Avenue		
City:	Waltham		
State/Country:	MASSACHUSETTS		
Postal Code:	02451		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	78457079	SYNFUSION	
Serial Number:	78449605	SYNTONIX	
Serial Number:	78158053	TRANSCEPTOR	
CORRESPONDENCE DATA			
Fax Number:	(617)526-5000		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	6175266448		
Email:	janey.davidson@wilmerhale.com		
Correspondent Name:	Michael J. Bevilacqua, Esquire		
Address Line 1:	Wilmer Cutler Pickering Hale and DorrLLP		
Address Line 2:	60 State Street		
Address Line 4:	Boston, MASSACHUSETTS 02109		
NAME OF SUBMITTER:	Michael J. Bevilacqua		
Signature:	/michael j. bevilacqua/		

OP \$90.00 78457079

Date:

07/07/2006

Total Attachments: 2

source=termination syntonix bay city#page1.tif

source=termination syntonix bay city#page2.tif

TERMINATION OF SUPPLEMENT TO TRADEMARK SECURITY AGREEMENT

WHEREAS, Syntonix Pharmaceuticals, Inc., a Delaware corporation (the "Grantor"), and The Bay City Capital Fund III, L.P., a Delaware limited partnership, as agent (the "Agent") for Venrock Associates, Venrock Associates II, L.P., Venrock Entrepreneurs Fund III, L.P., Alta BioPharma Partners II, L.P., Alta Embarcadero BioPharma Partners II, LLC, AEW 2000, LP, The AFB Fund LLC, A.M. Pappas Life Science Ventures II, L.P., Biomedicine, L.P., The Bay City CapitalFund III, L.P., in its capacity as a lender, and The Bay City Capital Fund III Co-Investment Fund L.P. (the "Lenders"), entered into a certain Supplement to Trademark Security Agreement (the "Supplement"), dated April 30, 2005, to the Trademark Security Agreement (the "Trademark Security Agreement"), dated as of May 12, 2004, which was recorded in the United States Patent and Trademark Office on May 16, 2005 at Reel 3090 and Frame 0731, that by its terms granted the Agent a security interest in certain trademarks (the "Trademarks") listed in Schedule 1 to the Supplement and all trademark applications and registrations, acquired or arising after the date of the Supplement;

WHEREAS, the Grantor has or has caused to be paid and satisfied in full the obligations for which the security interest in the Trademarks was granted.


NOW THEREFORE the parties hereto agree that the Agent hereby releases, effective as of December 14, 2005, its interest in the Trademarks listed on Schedule 1 of the Supplement and attached here on Exhibit A in which the Agent was granted a security interest under the Supplement. The Agent also hereby releases its security interest in the Trademarks listed in Exhibit A attached hereto. The Agent further agrees, for itself, its successors and assigns, to execute such further documents and to perform such further lawful acts as may reasonably be requested by the Grantor, to effectuate this Termination.

IN WITNESS WHEREOF the parties hereto by the signature below of their duly authorized representatives agree to be bound by the provisions of this Termination Agreement as of the date of execution, this 7th day of July, 2006.

THE BAY CITY CAPITAL FUND III, L.P.
as Agent for the Lenders

By: Bay City Capital Management III LLC
Its: General Partner

By: Bay City Capital LLC
Its: Manager

By: 
Name: CARL GOLDFISHER
Title: MANAGER & MANAGING DIRECTOR

SYNTOX PHARMACEUTICALS, INC.
as Grantor

By: 
Name: John W. Rippe
Title: CEO

Exhibit A

<i>Mark</i>	<i>Serial No.</i>	<i>Filing Date</i>
SYNFUSION	78/457079	July 27, 2004
SYNTONIX	78/449605	July 13, 2004
TRANSCEPTOR	78/158053	August 27, 2002